Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divi...

ver descrição completa

Detalhes bibliográficos
Autores: Oñate, Guadalupe, García-Ávila, Sara, Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/59257
Acesso em linha:http://hdl.handle.net/10230/59257
http://dx.doi.org/10.1038/s41408-023-00839-1
Access Level:acceso abierto
Palavra-chave:Acute myeloid leukaemia
Translational research
id ES_a7a159e16eebc3e2d6949d1270eeae64
oai_identifier_str oai:recercat.cat:10230/59257
network_acronym_str ES
network_name_str España
repository_id_str
spelling Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohortOñate, GuadalupeGarcía-Ávila, SaraSpanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)Acute myeloid leukaemiaTranslational researchMidostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divided into an early (2012-2015) and late (2016-2020) cohorts. They were uniformly treated except for the addition of midostaurin in 71% of late group patients. No differences were observed in response rates or the number of allotransplants between groups. Outcome was improved in the late period: 2-year relapse incidence decreased from 42% vs 29% in early vs late group (p = 0.024) and 2-year overall survival (OS) improved from 47% vs 61% (p = 0.042), respectively. The effect of midostaurin was evident in NPM1mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011) and mitigated FLT3-ITD allelic ratio prognostic value: 2-yr OS with midostaurin was 85% and 58% in low and high ratio patients (p = 0.049) vs 67% and 39% in naive patients (p = 0.005). In the wild-type NPM1 subset (n = 75), we did not observe significant differences between both study periods. In conclusion, this study highlights the improved outcome of FLT3mut AML fit patients with the incorporation of midostaurin.Nature Research202420242023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/59257http://dx.doi.org/10.1038/s41408-023-00839-1reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésBlood Cancer Journal. 2023 May 5;13(1):69© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/592572026-05-29T05:05:01Z
dc.title.none.fl_str_mv Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
title Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
spellingShingle Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
Oñate, Guadalupe
Acute myeloid leukaemia
Translational research
title_short Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
title_full Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
title_fullStr Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
title_full_unstemmed Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
title_sort Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
dc.creator.none.fl_str_mv Oñate, Guadalupe
García-Ávila, Sara
Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
author Oñate, Guadalupe
author_facet Oñate, Guadalupe
García-Ávila, Sara
Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
author_role author
author2 García-Ávila, Sara
Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
author2_role author
author
dc.subject.none.fl_str_mv Acute myeloid leukaemia
Translational research
topic Acute myeloid leukaemia
Translational research
description Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divided into an early (2012-2015) and late (2016-2020) cohorts. They were uniformly treated except for the addition of midostaurin in 71% of late group patients. No differences were observed in response rates or the number of allotransplants between groups. Outcome was improved in the late period: 2-year relapse incidence decreased from 42% vs 29% in early vs late group (p = 0.024) and 2-year overall survival (OS) improved from 47% vs 61% (p = 0.042), respectively. The effect of midostaurin was evident in NPM1mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011) and mitigated FLT3-ITD allelic ratio prognostic value: 2-yr OS with midostaurin was 85% and 58% in low and high ratio patients (p = 0.049) vs 67% and 39% in naive patients (p = 0.005). In the wild-type NPM1 subset (n = 75), we did not observe significant differences between both study periods. In conclusion, this study highlights the improved outcome of FLT3mut AML fit patients with the incorporation of midostaurin.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/59257
http://dx.doi.org/10.1038/s41408-023-00839-1
url http://hdl.handle.net/10230/59257
http://dx.doi.org/10.1038/s41408-023-00839-1
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Blood Cancer Journal. 2023 May 5;13(1):69
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415794430967808
score 15,81155

Registos relacionados